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Abstract
Background: The objective of the study was to investigate the effect of different types of bile acids on
proliferation of cholangiocarcinoma and the potential molecular mechanisms.
Methods: PCR assay and Western blot were performed to detect the expression of farnesoid × receptor (FXR) in
mRNA and protein level. Immunohistochemical analysis was carried out to monitor the expression of FXR in
cholangiocarcinoma tissues from 26 patients and 10 normal controls. The effects on in vivo tumor growth were
also studied in nude mouse model.
Results: Free bile acids induced an increased expression of FXR; on the contrary, the conjugated bile acids
decreased the expression of FXR. The FXR effect has been illustrated with the use of the FXR agonist GW4064 and
the FXR antagonist GS. More specifically, when the use of free bile acids combined with FXR agonist GW4064, the
tumor cell inhibitory effect was even more pronounced. But adding FXR antagonist GS into the treatment
attenuated the tumor inhibitory effect caused by free bile acids. Combined treatment of GS and CDCA could
reverse the regulating effect of CDCA on the expression of FXR. Administration of CDCA and GW 4064 resulted in
a significant inhibition of tumor growth. The inhibitory effect in combination group (CDCA plus GW 4064) was
even more pronounced. Again, the conjugated bile acid-GDCA promoted the growth of tumor. We also found that
FXR agonist GW4064 effectively blocked the stimulatory effect of GDCA on tumor growth. And the characteristic
and difference of FXR expressions were in agreement with previous experimental results in mouse
cholangiocarcinoma tissues. There was also significant difference in FXR expression between normal and tumor
tissues from patients with cholangiocarcinoma.
Conclusions: The imbalance of ratio of free and conjugated bile acids may play an important role in
tumorigenesis of cholangiocarcinoma. FXR, a member of the nuclear receptor superfamily, may mediate the effects
induced by the bile acids.
Background
Cholangiocarcinoma is notoriously difficult to diagnose
and is associated with high mortality [1]. At diagnosis,
most cases become inoperable [2]. Patients with cholan-
giocarcinoma respond extremely poorly to the conven-
tional chemotherapy and radiation therapy. Thus, there
is an urgent need to develop effective new therapeutic
strategies.
It is known that the balance of various bile acids is
crucial to lipid metabolism. Significant progress has
occurred in the understanding of their roles in
carcinogenesis [3,4]. The “Toxic Bile” concept has been
proposed to explain the effects of bile acids on chole-
static liver diseases [5]. Other than cholelithiasis, studies
have also found that there is an excess risk of forming
m a l i g n a n tt u m o r si ns o m eo r g a n se x p o s e dt oh i g hc o n -
centration of bile acids, such as in the gastrointestinal
tract [6]. Several epidemiologic studies have implicated
that the alterations of the composition of bile acids
increased the incidence of colorectal adenocarcinoma
[7]. Additionally, bile acids were found to stimulate cell
metaplasia in the mucosa of the stomach [8]. According
to Mühlbauer’s report, conjugated bile acid could stimu-
late NF-B pathway and regulate the expression of
inflammatory factors, leading to abnormal proliferation
of epithelial cells in the colon [9]. Dvrok and Wehbe
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stimulated tumor growth due to chronically elevated IL-
6 expression [10,11]. In view of previous studies, bile
acids are thought as not only the metabolic products of
lipid metabolism, but also as possible tumor regulating
factors. However, there are a number of important ques-
tions yet to be answered. 1) Do changes in the human
bile acid composition affect the activation of nuclear
receptors and cell signaling pathways in the cholangio-
carcinoma in a physiologically significant way? 2) What
is the underlying molecular mechanism of various types
of bile acids on the occurrence and development of
cholangiocarcinoma?
Farnesoid × receptor (FXR) is a nuclear receptor for
bile acids, which is very important in bile acid homeos-
tasis, as well as in glucose and lipid metabolism [12-14].
FXR consists of two primary domains, the DNA binding
domain and the ligand binding domain. Through these
functional domains, extranuclear signaling can be con-
veyed to the specific DNA site. Recent studies have
demonstrated that the function of FXR is also related to
the pathological process of cholangiocarcinoma [15,16].
Yang and Kim observed spontaneous hepatic cancer and
cholangiocarcinoma in FXR-null mice [17,18]. In addi-
tion, it was reported that up-regulation of FXR by its
agonist could induce cell apoptosis [16,19,20]. All of the
a b o v es t u d i e ss t r o n g l ys u g g e s tt h a tF X Rm i g h tp l a ya
key role in the tumor occurrence and development. As
reported in literature, FXR agonist could inhibit other
nuclear factors which controlled cell growth, apoptosis
or tumorigenesis [16].
In our previous study, we found that free bile acids
caused dose- and time-dependent inhibition of cholan-
giocarcinoma cells, whereas the conjugated form caused
dose- and time-dependent stimulation [21]. Here, we
focused our research on FXR and its role in the function
of bile acids in mouse and human tumor tissues, to bet-
ter understand the molecular mechanisms underlying
the effect of bile acids on cholangiocarcinoma.
Methods
1. Cell culture and agents
Human cholangiocarcinoma cell line QBC 939 was
obtained from Shanghai TongjiU n i v e r s i t y( S h a n g h a i ,
China). The cells were maintained in a 37°C RPMI-1640
medium (Invitrogen, CA, USA), and the culture was
kept in a humidified atmosphere of 5% CO2 and supple-
mented with 10% fetal bovine serum (Biowest, Madrid,
Spain). Sodium salts of free bile acids-cholic acid (CA),
deoxycholic acid (DCA), chenodeoxycholic acid
(CDCA), and their glycine conjugates-glycocholic acid
(GCA), glycochenodeoxycholic acid (GDCA) and glyco-
chenodeoxycholic acid (GCDCA) were purchased from
Sigma Corp (St Louis, MO). GS, a FXR antagonist, was
purchased from Calbiochem Corp (San Diego, CA).
GW4064, a FXR agonist, was purchased from Tocris
Corp. (Ellisville, MO).
Cells were cultured overnight before treatment. Next
day, six different bile acids (CA 200 μmol/L; DCA 200
μmol/L; CDCA 200 μmol/L; GCA 800 μmol/L; GDCA
400 μmol/L; GCDCA 400 μmol/L) were added to the
cell culture for 48 hours.
2. Treatment of xenograft tumor in nude mice
To form the xenograft tumors, 2 × 10
6 cells were
injected subcutaneously into the nude mice. 14 days
later, the volume of the tumors reached about 100 mm
3.
Then, 36 mice were randomized into six groups. In the
control group, mice were fed with 100 μls t e r i l ew a t e r
and intraperitoneally injected with 100 μl DMSO. In the
CDCA group and GDCA group, mice were fed with dif-
ferent bile acids (400 mg/kg) and intraperitoneally
injected with 100 μl DMSO. In the GW4064 group
(GW4064, a synthetic FXR agonist, Tocris Corp., UK),
mice were intraperitoneally injected with GW4064 (30
mg/kg) and fed with 100 μl sterile water. In the com-
bined treatment groups, mice were injected with
GW4064 combined with feeding of CDCA or GDCA.
After the treatment, all mice were kept in a lamina flow
environment for another 7 days and the volume of the
xenograft was recorded before and after the treatment
according to the following formula: V = (length ×
width
2)/2.
3. RNA preparation and PCR assay (RT-PCR and real-time
PCR)
Total RNA was isolated using Trizol reagent (Invitrogen,
CA, USA.) according to the manufacturer’s recommen-
dation. After being washed with 75% ethanol, the final
RNA extracts were eluted in 20 μl distilled diethyl pyro-
carbonate-treated water. The concentration and purity
of RNA were measured using a spectrophotometer. The
complementary DNA was synthesized according to the
manufacturer’s instruction (Fermentas, Canada). The
PCR primers for FXR and GAPDH gene amplification
were as follows: FXR’sf o r w a r d5 ’-acaatccaaggaggtagaa-
gac-3’, reverse 5’-gaagaaatccaggaaactaagag-3’;G A P D H ’s
forward 5’-ccctgttgctgtagccaaattc-3’,r e v e r s e5 ’-
acccactcctccacctttga-3’. The conditions consisted of 40
cycles of denaturation at 90°C for 30 s, annealing at 55°
C for 30 s and extension at 72°C for 60 s in a PTC0200
thermal cycle system (Bio-Rad, CA, USA). The RT-PCR
products were examined by electrophoresis on a 2%
agarose gel and quantified by grey levels measurements.
The real-time PCR assay was measured in Light Cycler
480 Real-Time PCR System (F. Hoffmann-La Roche,
Ltd) under the following conditions: 40 cycles of pre-
denaturation at 90°C for 10 s, denaturation at 90°C for
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were as follows: FXR’sf o r w a r d5 ’-GATTGCTTTGCT-
GAAAGGGTC-3’, reverse 5’-CAGAATGCCCAGACG-
GAAG-3’. b-actin’sf o r w a r d5 ’-TTGCTGATCCA
CATCTGCT-3’ reverse 5’-GACAGGATGCAGAAGGA-
GAT-3’.G A P D Hw a su s e da sa ni n t e r n a lc o n t r o lf o r
RT-PCR and b-actin was used as an internal control of
real-time PCR.
4. Western blot analysis
Proteins were extracted using a nuclear and cytoplasm
extraction kit (Pierce Biotechnology, IL, USA). Western
blot analysis was performed as described previously [22].
Rabbit anti human FXR antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) was diluted to 1:1000. Antibody
binding were detected using the Odyssey Infrared Image
S-120 system (Li-cor Inc, CA). TBP (Santa Cruz Bio-
technology, Santa Cruz, CA) levels were used as internal
controls. TBP, TATA-binding protein, a kind of nucleo-
protein, served as the loading control for FXR. And we
used grey level to quantify FXR expression.
5. Immunohistochemical analysis
After obtaining informed consent from patients and
after receiving the approval of the ethics committee, a
total of 26 patients with cholangiocarcinoma undergoing
elective surgery were entered sequentially, into this
prospective study. We also collected 10 normal bile duct
tissues from donors for transplantation. Tissues
obtained from the nude mice and patients were fixed in
paraformaldehyde and paraffin wax for further analysis.
Immunohistochemical analysis was performed as
described previously [22]. Anti FXR antibodies was
diluted to 1:50. Every slide was reviewed by two pathol-
ogists via double blind observation procedures. Immu-
nostaining scores were calculated based on the
percentage of immunostained cells and the intensity
score. Immunostaining intensity scores were calculated
by using the following formula: weighted signal intensity
= percentage of immunostained cells × average intensity
score. The definition for the calculated scores is as fol-
lowing: 0 point as negative staining; 1~2 points as slight
staining (+); 3~4 points as moderate staining (++); 5~6
points as strong staining (+++). We also used Zeiss sys-
tem to analyze positive rate and made a histogram to
describe the difference between control group and trea-
ted groups.
6. Statistical analysis
D a t aw e r es h o w na sm e a nv a l u e s±S . E .a n dS A S8 . 0
software (SAS Institute, USA) was used for statistical
analysis. Student’s t-test (two-tail) was used throughout
the present study and Kruskal-Wills test was used to
analyze the expression of FXR in cholangiocarcinoma
Figure 1 Bile acids regulated the expression of FXR. A, RT-PCR analysis showed that free bile acids (CA, DCA, CDCA) enhanced the mRNA
expression of FXR whereas conjugated bile acids (GCA, GDCA, GCDCA) decreased FXR mRNA level. GAPDH served as the loading control. B,
Realtime-PCR analysis showed that differences of FXR mRNA expression according to density level after CDCA and GDCA treatment. b-actin
served as an internal control. C, The protein expression of FXR was tested by Western blot. Free bile acids increased the expression of FXR, while
conjugated bile acids decreased the expression of the FXR protein. TBP (TATA-binding protein, a kind of nucleoprotein) served as the loading
control.
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tistically significant for p < 0.05.
Results and Discussion
To determine whether FXR expression is responsible for
the changes in cell viability and apoptosis, we used regu-
lar RT-PCR and real-time PCR to detect the mRNA
expression of FXR and Western blot to compare the
protein expression of FXR. Our results showed that the
expression of FXR was altered by different bile acids.
The free bile acids (CA, DCA and CDCA) induced an
increase in the mRNA (Figure 1A,B) and protein expres-
sion (Figure 1C) of FXR. On the contrary, treatment by
the conjugated bile acids (GCA, GDCA and GCDCA)
decreased the mRNA and protein expression of FXR.
According to density level, the mRNA expression of
FXR was detected as 1.16 folds (200 μMC Ag r o u p ) ,
1.12 folds (200 μM DCA group), 1.16 folds (200 μM
CDCA group), 0.60 folds (800 μMG C Ag r o u p ) ,0 . 6 1
folds (400 μM GDCA group) and 0.61 folds (400 μM
GCDCA group), compared with the control group. In
the part of real-time PCR assay, it indicated that CDCA
increased mRNA expression as 1.14 folds of control,
while GDCA decreased the expression of FXR mRNA as
0.79 folds of control. And the protein expression of FXR
was 1.56 folds (200 μM CA group), 1.24 folds (200 μM
DCA group), 1.25 folds (400 μM CDCA group), 0.23
folds (800 μM GCA group), 0.23 folds (400 μMG D C A
group) and 0.35 folds (400 μM GCDCA group). The
results indicated that bile acid regulated the cell growth
through its physiological receptor FXR, which has been
reported to be related to the signal transduction of cell
growth [23-26]. FXR is a member of the nuclear recep-
tor superfamily, which contains thyroid hormones, ster-
oid hormones, retinoid and orphan nuclear receptors.
FXR can bind to specific DNA sequences and activate
gene transcription by forming a heterodimer with reti-
noid × receptor. Besides biliary cancer, FXR has also
been implicated and associated with breast cancer [26]
and colon cancer [27]. In contrast to its well-established
mechanism in regulating bile acid homeostasis, little is
known about how FXR functions in carcinogenesis. In
our experiment, besides the changes in cell viability and
apoptosis caused by different bile acids, changes in the
expression of the bile acid receptor FXR were also
observed. We also found that the alteration of FXR
expression was inversely proportional to the change of
cell growth. These results suggest that FXR is an impor-
tant signaling receptor when cells are treated with bile
acids. We speculate that the tumorigenesis may initiate
due to decreased FXR expression. This is consistent
with previous study findings that deficiency of FXR
could lead to cell oxidative stress injury and hyperplasia
[28].
Since the expression of FXR is closely related to can-
cer cell growth, interventions to manipulate FXR levels
may eventually benefit patients with cholangiocarci-
noma. As shown in Figure 2A, free bile acids CA, DCA
and CDCA significantly reduced cell proliferation of
cholangiocarcinoma cells, the inhibition rate was 46.7%
(CA 200 μmol/L), 51.5% (DCA 200 μmol/L) and 78.5%
(CDCA 200 μmol/L) respectively (p < 0.05, compared
with the control group). When combined with GW4064,
the inhibitory effect of the free bile acids on cell growth
was even more pronounced (inhibition rate: 91.8%,
93.1% and 92.3%, respectively). On the contrary, adding
GS into the treatment attenuated the inhibitory effect
caused by free bile acids. The inhibition rate in GS and
free bile acid combination group was reduced to 7.74%,
Figure 2 FXR antagonist/agonist changed the effects of bile
acids on FXR expression. A, combination of GS (FXR antagonist)
or GW 4064 (FXR agonist) with free bile acids. B, combination of GS
or GW 4064 with conjugated bile acids. C, bile acids and FXR
antagonist/agonist changed the expression of FXR. TBP: TATA-
binding protein (loading control). * p < 0.05, compared with the
control group. # p < 0.05, compared with bile acid treatment
groups.
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enhanced cholangiocarcinoma cell growth significantly
(Figure 2B). However, GW4064 reversed the effect of
conjugated bile acids on QBC 939 cells. When the con-
jugated bile acids were combined with GW4064, cell
viability was significantly decreased (inhibition rate:
65.7%, 65.6% and 64.1%, p < 0.05). When the conjugated
bile acids were combined with GS, the stimulatory effect
of the conjugated bile acids on cell growth was
abrogated.
We next used FXR antagonist or agonist to co-treat
with either free or conjugated bile acids, and detected
the protein expression of FXR. As shown in Figure 2C,
free bile acids increased the expression level of FXR.
Combined treatments of GS and CDCA could reverse
the regulating effect of CDCA on the expression of
FXR. Additionally, when treating cells with conjugated
bile acids-GDCA, FXR expression was decreased. When
treating cells with both FXR agonist-GW4064 and con-
jugated bile acid-GDCA, the effect caused by GDCA
alone was reversed.
To further assess the results in vivo, we used a nude
mouse model to determine the effect of bile acids on
cholangiocarcinoma (Figure 3A). Tumor volume at the
end of the experiment was 0.279 ± 0.068 cm
3 and 0.228
±0 . 1 1 6c m
3 (n = 6) in animals receiving CDCA and
GW 4064, respectively. Administration of CDCA and
GW 4064 resulted in a significant (P < 0.05) inhibition
of tumor growth in both sets of animals compared with
control group (tumor volume: 0.609 ± 0.089 cm
3). The
inhibitory effect in combination group (CDCA plus GW
4064) was even more pronounced when compared with
control group (tumor volume: 0.120 ± 0.046 cm
3 vs.
0.609 ± 0.089 cm
3, respectively; P <0 . 0 5 ) .A g a i n ,t h e
conjugated bile acid-GDCA promoted the growth of
tumor (tumor volume: 1.021 ± 0.272 cm
3; p < 0.05,
compared with the control group). In addition, we
found that FXR agonist GW4064 effectively blocked the
stimulatory effect of GDCA on tumor growth. The
volumes of tumor xenografts in the combination of
GDCA and GW4064 group were similar to data in the
control group (Table 1).
We also performed immunohistochemistry staining to
determine the degree of FXR expression in mouse cho-
langiocarcinoma tissue. We found the similar results of
FXR expressions. As shown in Figure 3B, there were
Figure 3 Effect of bile acids and GW4064 (FXR agonist) on tumor growth in vivo. A, effect of bile acids and GW4064 on tumor growth in
vivo. The mean volumes of tumor in CDCA and GW 4064 were much less than those of CON group, GDCA group and GDCA+GW 4064 group
due to the enhancement of FXR expression. The inhibitory effect in CDCA plus GW 4064 group was even more pronounced. (* p < 0.05). Left
panel: tumors at the end of the experiment; right panel: quantitative measures of the tumor volumes. B, Immunohistochemical staining for FXR
expression in mice xenograft tissues. Right panel: quantitations of FXR expression in different groups; left panel: representative immunostaining
of FXR expression in the tumor tissues. Black arrows point to positive cells.
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in CDCA treatment group was 46.09% and 62.64% in
GW4064 treatment group. CDCA and GW4064 worked
synergistically on the expression of FXR, because the
positive rate increased to 67.09%. The results also
revealed that GDCA reduced the expression of FXR to
8.80%, but GW4064 reversed the effect (the positive rate
was 23.00%).
Finally, we examined the expression of FXR in cholan-
giocarcinoma tissues from 26 patients and 10 controls.
As shown in Figure 4, FXR expression was mild in
65.4% and moderate in 34.6% of the tumor tissues
(Figure 4C). However, FXR was expressed strongly in
60% and moderately in 40% of the normal tissues (Fig-
ure 4B). There was strong staining of FXR in the
nucleus of the normal bile duct, which reflected the
high expression of FXR in normal tissue. However, in
cholangiocarcinoma tissue, few cells had the nuclear
staining for FXR, reflecting the reduced expression of
FXR in tumor tissue. Result of Kruskal-Wills test indi-
cates significant statistical difference of FXR expression
between normal and tumor tissues. These results indi-
cate that FXR could be a protective factor for tumor
development.
Table 1 The Change of Tumor Volume before and after Treatment
Group Volume D0
(cm
3)
Volume D3
(cm
3)
Volume D5
(cm
3)
Volume D7
(cm
3)
Volume Change
(cm
3)
CON 0.086 ± 0.015 0.149 ± 0.022 0.407 ± 0.056 0.609 ± 0.089 0.523 ± 0.083
GDCA 0.102 ± 0.024 0.250 ± 0.065 0.688 ± 0.176 1.021 ± 0.272 0.919 ± 0.282*
GDCA+GW4064 0.086 ± 0.046 0.106 ± 0.063 0.261 ± 0.188 0.393 ± 0.287 0.307 ± 0.260
CDCA 0.114 ± 0.028 0.155 ± 0.040 0.187 ± 0.046 0.279 ± 0.068 0.164 ± 0.080*
GW4064 0.115 ± 0.023 0.101 ± 0.035 0.154 ± 0.078 0.228 ± 0.116 0.113 ± 0.130*
CDCA+GW4064 0.092 ± 0.031 0.081 ± 0.031 0.104 ± 0.024 0.120 ± 0.046 0.027 ± 0.054*
*p < 0.05, the treatment group compared with the control group. D: day
Figure 4 Expression of FXR in cholangiocarcinoma tissues from patients. Tissues from 26 patients and 10 normal controls were obtained.
Immunostaining for FXR expression was done. A, negative control for immunostaining. B, FXR expression in normal biliary ducts. C, FXR
expression in cholangiocarcinoma tissues. The FXR expression was quantitated according to staining intensity and reported as mild (+), moderate
(++) and strong (+++), respectively. The results were summarized in the table.
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laboratory and hope to develop a new therapeutic strat-
egy for cholangiocarcinoma. Furthermore, our prelimin-
ary studies have shown that there are intriguing linkages
between FXR and NF-kappa B pathway (data not
shown). In the human cholangiocarcinoma tissues, we
have not only found the decrease of FXR expression,
but also noticed an unusual increase of p-IkB. On the
opposite, p-IkB was very rarely observed in normal tis-
sue. Because the level of p-IkB can reflect indirectly the
activation of NF-kappa B pathway, we therefore propose
that the effect of bile acids on tumor growth is related
to NF-kappa B pathway. Novel agents are being devel-
oped for cancer therapy [29-32]. We believe that study
of FXR expression on bile acid signaling pathway could
be useful for development of novel therapy for
cholangiocarcinoma.
Conclusions
The imbalance of free and conjugated bile acids ratio
may play an important role in tumorigenesis of cholan-
giocarcinoma. FXR, a member of the nuclear receptor
superfamily, may also mediate the effects induced by the
bile acids. Regulating the balance of free/conjugated bile
acids as well as activating/inhibiting FXR might provide
promising therapeutic approaches to treating cholangio-
carcinoma patients.
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